November 9, 2017 / 1:19 PM / a month ago

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

Nov 9 (Reuters) - Protagonist Therapeutics Inc:

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

* Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below